Selective Retina Therapy With Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03339856|
Recruitment Status : Completed
First Posted : November 13, 2017
Last Update Posted : November 13, 2017
Selective retina therapy (SRT) selectively disrupts the retinal pigment epithelium (RPE) with minimal damage to the photoreceptors. Previous studies have shown SRT to be effective for resolving SRF, while causing only minimal collateral damage to the retina and vision.However, most patients included in prior studies had chronic CSC (≥3 months symptom duration) and SRT efficacy on acute CSC is not fully known.
The current study evaluated short-term treatment outcomes following SRT with real-time feedback-controlled dosimetry in Korean patients with acute idiopathic CSC.
|Condition or disease||Intervention/treatment||Phase|
|Central Serous Chorioretinopathy||Device: Selective retina therapy||Not Applicable|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||16 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Selective Retina Therapy With Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients|
|Actual Study Start Date :||January 1, 2017|
|Actual Primary Completion Date :||September 1, 2017|
|Actual Study Completion Date :||October 1, 2017|
Experimental: Treatment arm
Patients received selective retina therapy
Device: Selective retina therapy
The selective retina therapy (SRT) is a laser treatment to the retina using the R:GEN device (Lutronic, Goyang-si, South Korea).
Laser energy began at 80 µJ and was increased in 5-10 µJ intervals until the optimal energy delivery was confirmed by the RFD system. Following confirmation, the optimal laser energy was applied to fluorescein leakages. If the energy was indeed optimal at leakage points, laser shots were administered around the leakages. If the energy was not optimal at the leakage points, laser energy was again increased in 5-10 µJ increments until optimal energy delivery.
- Subretinal fluid [ Time Frame: 3 months after treatment ]Presence or absence of subretinal fluid which identified based on optical coherence tomography images.
- Visual acuity [ Time Frame: At diagnosis, at 1 month, and 3 months after treatment ]Changes in logarithm of minimal angle of resolution visual acuity during the follow-up, which measured using visual acuity chart.